Mark Mallon — EVP-Global Product & Portfolio Strategy, Medical Affairs, Corporate Affairs & International West at Astrazeneca PLC

Mr. Mark Mallon has been an Executive Vice-President of Global Product & Portfolio Strategy, Global Medical Affairs and Corporate Affairs at AstraZeneca PLC since May 3, 2017. Mr. Mallon served as an Executive Vice President of Global Product & Portfolio Strategy, Global Medical Affairs & Corporate Affairs at AstraZeneca PLC since August 2016 until May 3, 2017 and served as its Executive Vice-President of International West. Mr. Mallon served as Executive Vice President of International at AstraZeneca PLC since January 2013 until August 2016. Mr. Mallon served as the President at AstraZeneca China Limited. He served as Executive Vice President, Chief Executive Officer and Representative Director at AstraZeneca (Japan), having taken charge of all affairs in Japan market. He served as a Vice President of Marketing & Sales Operations of AstraZeneca Pharmaceuticals LP and led the marketing, sales, commercial operations and commercial managed markets organizations. He was responsible for the AZ Healthcare Innovation Center and for identifying, developing and implementing new practices within the US business. He served as Marketing Company President for Italy and a member of AstraZeneca Pharmaceuticals LP's European Management Team. Mr. Mallon began his career here in 1994, as a Promotions Team Leader at Astra Merck. Over the years, he held many key positions in marketing and sales. As the original leader of AstraZeneca Pharmaceuticals LP's GI/respiratory area, he was instrumental in the launch of three new products - Entocort EC, Prilosec OTC and NEXIUM?? (esomeprazole magnesium). He received his Bachelor's Degree in engineering from the University of Pennsylvania and a Master of business administration from the Wharton School of Business, University of Pennsylvania.